VACCINE STABILIZATION and MANUFACTURING
One of the goals of BLUE LION BIOTECH’s vaccines program is the stabilization of vaccines that are made of whole organisms, vaccine subunits, nucleic acids, and novel delivery, microencapsulation and nanotechnology. Focus is on non-needle delivery as described above.
BLUE LION BIOTECH'S partner, INCELL has a commitment to accelerating cost-effective product development and to “breaking the cold chain” for vaccines and other heat-labile products, new formulas, protectants and alternate packaging. BLUE LION BIOTECH is developing innovative approaches that will help break the cold chain for vaccine transport and delivery and thus reduce the product costs and increase the probability that the vaccine or therapy remains active and was not compromised in the transport process.
This work is being done with an extensive collaborative network of companies, academic investigators and government agencies, including:
- NanoRelease Technologies, LLC (NRT)
- Center for Microencapsulation and Drug Delivery (CMDD) at Texas A&M Health Science Center
- Department of Defense
- Many More to be added